Meropenem pharmacokinetics in the newborn. by Anker, J.N. van den et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/79549
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
  Published Ahead of Print 6 July 2009. 
10.1128/AAC.00351-09. 
2009, 53(9):3871. DOI:Antimicrob. Agents Chemother. 
Drusano and Fritz Sorgel
Kinzig-Schippers, Jirina Martinkova, Ronald de Groot, G. L. 
John N. van den Anker, Pavla Pokorna, Martina
 
Newborn
Meropenem Pharmacokinetics in the
http://aac.asm.org/content/53/9/3871
Updated information and services can be found at: 
These include:
REFERENCES
http://aac.asm.org/content/53/9/3871#ref-list-1
This article cites 26 articles, 5 of which can be accessed free at:
CONTENT ALERTS
 more»articles cite this article), 
Receive: RSS Feeds, eTOCs, free email alerts (when new
http://journals.asm.org/site/misc/reprints.xhtmlInformation about commercial reprint orders: 
http://journals.asm.org/site/subscriptions/To subscribe to to another ASM Journal go to: 
 o
n
 July 12, 2012 by Universiteitsbibliotheek
http://aac.asm
.org/
D
ow
nloaded from
 
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 2009, p. 3871–3879 Vol. 53, No. 9
0066-4804/09/$08.000 doi:10.1128/AAC.00351-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.
Meropenem Pharmacokinetics in the Newborn
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We studied meropenem in 23 pre-term (gestational age, 29 to 36 weeks) and 15 full-term (gestational age, 37 to
42 weeks) neonates. Meropenem doses of 10, 20, and 40 mg/kg were administered as single doses (30-min intra-
venous infusion) on a random basis. Blood was obtained for determining the meropenem concentration nine times.
Each child required other antimicrobials for proven/suspected bacterial infections. Samples were assayed by
high-performance liquid chromatography analysis. Population pharmacokinetic parameter values were obtained by
employing the BigNPAG program. Model building was performed by the likelihood ratio test. The final model
included estimated creatinine clearance (CLcr) (Schwartz formula) and weight (Wt) in the calculation of clearance
(meropenem clearance  0.00112  CLcr  0.0925 Wt  0.156 liter/hr). The overall fit of the model to the data
was good (observed  1.037  predicted  0.096; r2  0.977). Given the distributions of estimated creatinine
clearance and weight between pre-term and full-term neonates, meropenem clearance was substantially higher in
the full-term group. A Monte Carlo simulation was performed using the creatinine clearance and weight distribu-
tions for pre-term and full-term populations separately, examining 20- and 40-mg/kg doses, 8- and 12-h dosing
intervals, and 0.5-h and 4-h infusion times. The 8-h interval produced robust target attainments (both populations).
If more resistant organisms were to be treated (MIC of 4 to 8 mg/liter), the 40-mg/kg dose and a prolonged infusion
was favored. Treating clinicians need to balance dose choices for optimizing target attainment against potential
toxicity. These findings require validation in clinical circumstances.
In many countries, pre-term infants are frequently admitted
to the neonatal intensive care unit. Because of this, they fre-
quently suffer infections with nosocomially acquired organisms
(15, 24, 25). Meropenem, because of its broad-spectrum activ-
ity, which includes the majority of nosocomially acquired
pathogens, would be an agent of great utility in these circum-
stances.
Unfortunately, little information is available regarding the
disposition of antimicrobial agents in the neonatal patient pop-
ulation (22). This information is critical if the clinician is to be
able to prescribe the correct dose and schedule of an antimi-
crobial agent that will minimize toxicity and maximize the
probability of a good outcome. For -lactam antibiotics, the
work of a number of laboratories has indicated that the time
that plasma concentrations exceed the MIC of the pathogen is
the pharmacodynamic variable most closely linked to clinical
outcome (10). Therefore, the dosing interval which is selected
for antimicrobial administration will have a major impact on
the adequacy of the dose chosen.
Newborns are well known to have clearances of drugs which
differ from those seen in children and adults (2). Much of this
difference is attributable to the maturation of both renal and
nonrenal clearance pathways. Furthermore, volumes of distri-
bution (V) tend to be larger, when adjusted for weight, in
newborns than those seen in older children and adults (2).
Consequently, any evaluation of a new agent which does not
take into account physiological differences of newborn infants
relative to older children or adults will not be able to provide
optimal information to the clinician that will allow the choice
of the proper dosing interval to maximize the time above the
MIC (TimeMIC).
Because meropenem is such a potentially valuable agent for
the neonatally infected group, we decided to examine both
full-term and pre-term infants for their dispositions towards
meropenem. We report here the single-dose pharmacokinetic
parameters seen after doses of 10, 20, and 40 mg/kg of body
weight of meropenem in both pre- and full-term newborns.
MATERIALS AND METHODS
Patients and study design. Thirty-eight newborn infants were studied at two
centers: the Neonatal Intensive Care Units of the Erasmus MC-Sophia Chil-
dren’s Hospital, Rotterdam, The Netherlands, and Charles University, Prague,
Czech Republic. For inclusion in this clinical investigation, potential participants
were required to meet the following criteria. (i) Participants had to be hospital-
ized pre-term and full-term neonates in their first 4 weeks of life who had
received a minimum of 48 h of antibiotic therapy for a known or presumed
bacterial infection. (ii) The subject’s overall condition needed to be good or fair.
(iii) Parents or legal guardians needed to have given written informed consent.
* Corresponding author. Mailing address: Ordway Research Insti-
tute, 150 New Scotland Avenue, Albany, NY 12208. Phone: (518)
641-6410. Fax: (518) 641-6304. E-mail: gdrusano@ordwayresearch.org.
 Published ahead of print on 6 July 2009.
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(iv) The participants were not to meet any of the following exclusion criteria: (a)
so severely ill that they were not likely to survive the duration of the trial; (b)
born to mothers who are known or suspected to be positive for human immu-
nodeficiency virus or have hepatitis; (c) born to mothers who are addicted to
drugs or alcohol; (d) having a major congenital abnormality; (e) having a known
history of immediate hypersensitivity to any -lactam antibiotic; (f) having sei-
zures within the previous 3 days; (g) having unconjugated bilirubin concentra-
tions sufficiently high enough to warrant exchange transfusion; (h) having re-
ceived ceftriaxone or cefotoxin (known to interfere with the meropenem assay)
within the previous 3 days; (i) having plasma creatinine values of 140 mol/
liter; (j) having received a systemic investigational drug; or (k) having any con-
dition which in the opinion of the investigator made the subject unsuitable for
enrollment. All studied infants continued to receive their standard antibiotic
regimens. In addition, a single dose of meropenem was administered as a 30-min
intravenous infusion. The neonates were divided into a pre-term group (29 to 36
weeks of gestational age; n 23) and a group of full-term infants (37 to 42 weeks
of gestational age; n 15). Pre-term and full-term infants were further randomly
subdivided into three subgroups each. Each of the three groups was administered
one of the following doses: 10 mg/kg, 20 mg/kg, or 40 mg/kg of meropenem.
Informed consent. Written informed consent was obtained from the parents of
the infants according to institutional guidelines.
Sampling scheme and sample handling. Blood samples (200 l) were col-
lected immediately before and at the following time points after the start of the
infusion: 0.25, 0.5, 0.75, 1, 2, 4, 8, 12, and 24 h. Blood samples were collected into
NH4-heparinized tubes and shaken slightly. Blood samples were kept cold (4°C)
for at least 3 but no more than 15 min under centrifugation (4°C for 10 min at
3,500 rpm). The plasma was split and transferred into two plastic tubes. Samples
were quickly frozen on dry ice and maintained on dry ice until stored at 70°C.
Assay of meropenem in plasma and urine. The concentration of meropenem
in human plasma was determined by a precise high-performance liquid chroma-
tography procedure. The validation procedure followed international guidelines.
Briefly, an aliquot of plasma (30 l) was stabilized by an addition of 150 l of
0.05 M sodium phosphate buffer (pH 7.09) containing the internal standard
(cefpodoxime) and was deproteinated by adding 200 l of acetonitrile. After
vigorously mixing and centrifuging the samples, the acetonitrile was removed by
extraction with 500 l of dichloromethane. After centrifugation, 100 l of the
aqueous phase of each sample was injected onto the high-performance liquid
chromatography system. The chromatographic separation of meropenem from
endogenous material was performed and an internal standard was determined on
a Spherisorb ODS2 column (5 m, 250  4.6 mm), by using an isocratic solvent
system consisting of 0.05 M sodium dihydrogen phosphate buffer (pH 5.08) and
acetonitrile (90:10, vol/vol).
The retention times of meropenem and cefpodoxime were 9.0 and 12.8 min,
respectively. The eluent was monitored by UV absorption at 296 nm. The
Turbochrom 3 (version 3.2, 1991; PE Nelson, Cupertino, CA) software was used
for evaluation of the chromatograms. Calibration was performed by weighted
(1/concentration) linear regression. The flow rate was 0.6 ml/min.
The meropenem concentrations of 390 plasma samples from the study were
measured in a total of 15 sequences. Standard curves were prepared in blank
human plasma. The standard curve was linear between 0.0455 and 203 g/ml.
The limit of quantitation was 0.0455 g/ml. Fifty-one of the 390 samples were
below the limit of quantitation. The between-day coefficient of variation of the
spiked quality control samples ranged from 6.2 to 9.9%.
Pharmacokinetic methods. Population pharmacokinetic parameter estimation
for meropenem was performed using the NPAG (non-parametric adaptive grid
with adaptive ) program package developed by Leary et al. (20). This program
provides maximum-likelihood estimates of the population mean pharmacoki-
netic parameter values and their distributions without making assumptions as to
the shape of the underlying distributions. One- and two-compartment open
models with zero-order input and first-order elimination from the central com-
partment were evaluated. For observation weighting, the inverse of the assay
variance was employed as an approximation of the total observation variance.
This initial estimate was multiplied by a scalar (), which was iteratively esti-
mated to provide the best estimate of overall observation variance. The system
was parameterized as the V of the central compartment, the plasma clearance,
and the intercompartmental transfer rate constants.
Population analyses were performed for the population as a whole. Bayesian
posterior estimates of pharmacokinetic parameter values were derived for each
patient using that patient’s plasma samples and the probability density function
derived from the full population analysis.
We examined the dependence of total meropenem plasma clearance and V on
a number of demographic population descriptors. These descriptors included
sex, gestational age, weight (kg), heel-to-crown length (cm), creatinine clearance
(calculated according to the method of Schwartz et al. [23]), dose, and pre-term
versus full-term status. This analysis was performed using the generalized linear
module of the SYSTAT for Windows program (v. 11.0). Analyses were per-
formed both stepwise forward and stepwise backward. The level of significance
was set at an alpha equal to 0.05. This allowed us to examine the covariates to be
evaluated within the population model.
These analyses were performed by expanding the base pharmacokinetic
model. The significance of model expansion was determined by the likelihood
ratio test (twice the log-likelihood difference between the base and the expanded
model, examined against a 	2 distribution with the appropriate number of de-
grees of freedom).
In order to evaluate possible doses and schedules for recommendations for
pre-term and full-term infants, we employed the technique of Monte Carlo
simulation and evaluation of target attainment rates by MIC, as described pre-
viously (13). The ADAPT II package of programs of D’Argenio and Schumitzky
was employed for Monte Carlo simulation (6). Both normal and log-normal
distributions were evaluated. The choice between distributions was made by
determining the fidelity with which the starting parameter values and their
dispersions were recapitulated by the 9,999-subject simulation.
The simulations were carried out with the parameter values and creatinine
clearance and weight distributions for the full-term and pre-term infant popu-
lations considered separately.
RESULTS
Study population and clinical observations. All 38 newborn
infants, both pre-term and full-term, tolerated the single-dose
infusion of meropenem well. No drug-related adverse events
were identified. The demographic data of the 38 infants stud-
ied are presented in Tables 1 and 2. There were 23 pre-term
and 15 full-term newborn infants studied. The pre-term infants
consisted of 13 males and 10 females. Gestational ages ranged
TABLE 1. Demographic data and sequence of treatments of
hospitalized pre-term neonates
Center/
patient no. Sex
Gestational
age (wk) Wt (kg)
Crown-heel
length (cm)
CLcra
(ml/min/
1.73 m2)
Dosing
(mg/kg)
0001/0001 M 34 2.83 47.0 28.6 40
0001/0003 F 36 2.50 47.0 21.1 10
0001/0004 M 35 2.10 47.5 24.3 40
0001/0005 F 31 1.62 42.0 22.3 20
0001/0006 M 34 2.44 47.0 24.5 10
0001/0007 F 30 1.23 37.0 24.5 20
0001/0009 F 31 1.72 39.0 24.7 10
0001/0010 M 30 1.69 43.0 13.3 20
0001/0011 F 34 1.86 42.0 26.6 40
0001/0012 M 30 1.51 39.0 24.2 10
0001/0013 F 30 1.64 39.0 24.7 10
0001/0014 F 31 1.87 41.0 34.2 20
0001/0015 M 36 2.47 45.0 31.3 40
0001/0016 F 35 1.96 43.0 19.6 10
0001/0017 M 35 2.52 45.0 22.3 20
0002/0001 M 31 1.10 40.5 18.5 20
0002/0002 M 31 1.55 42.5 15.1 40
0002/0003 M 35 2.73 46.0 29.8 10
0002/0004 M 32 1.79 45.0 29.2 20
0002/0005 M 30 1.20 39.0 15.4 10
0002/0006 F 31 1.50 46.0 16.2 40
0002/0007 F 29 0.952 36.0 17.2 10
0002/0008 M 32 2.20 44.0 25.7 20
Mean 32 1.87 42.7 23.2
SD 2 0.53 3.43 5.53
Min 29 0.952 36.0 13.3
Max 36 2.83 47.5 34.2
a The creatinine clearance was calculated as follows: CLcr  0.45  crown-heel
length/plasma creatinine (2).
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from 29 to 36 weeks with weights ranging from 952 to 2,830 g
and the crown-heel length ranging from 36 to 47.5 cm. Post-
natal ages ranged from 2 to 28 days of life. Creatinine clear-
ance, calculated according to the method of Schwartz et al.
(30), ranged from 13.3 to 34.2 ml/min/1.73 m2. Nine pre-term
infants received 10 mg/kg of meropenem, while 8 received 20
mg/kg and 6 received 40 mg/kg of meropenem. The full-term
infants consisted of 10 males and 5 females. Their gestational
ages, weights, and crown-heel lengths ranged from 37 to 42
weeks, 2,340 to 4,050 g, and 43 to 53 cm, respectively. Postnatal
ages ranged from 2 to 14 days of life. The creatinine clearances
in this group, calculated according to the method of Schwartz
et al. (30), ranged from 20.1 to 60.3 ml/min/1.73 m2. In this
group, five infants received 10 mg/kg of meropenem, while five
received 20 mg/kg and five received 40 mg/kg of meropenem.
The antibiotics which were coadministered to the infants on
the day they received meropenem are as follows: amoxicillin,
ampicillin, azlocillin, cefuroxime, cefotaxime, ceftazidime, ox-
acillin, and ticarcillin (-lactams); amikacin, gentamicin, and
tobramycin (aminoglycosides); and lincomycin and vancomy-
cin (others). Other medications that were coadministered in-
clude caffeine, dobutamine, furosemide, hydrocortisone, indo-
methacin, and phenobarbital. While there are a number of
drugs which could potentially interfere with the tubular secre-
tion of meropenem, the administration of meropenem was
separated from the administration of potentially interfering
drugs as much as possible. Further, it should be recognized
that this is a particularly difficult patient population to study,
and they were studied while undergoing treatment for an in-
fection. The agents that we felt to be at the highest likelihood
of interfering with meropenem pharmacokinetics are as fol-
lows: amoxicillin, ampicillin, azlocillin, cefuroxime, cefotaxime,
ceftazidime, oxacillin, ticarcillin, and furosemide.
The mean plasma concentration-time curves for meropenem
for the 10-, 20-, and 40-mg/kg doses for pre-term infants are
displayed in Fig. 1A and data for the full-term infants are in
Fig. 1B. The peak concentrations are dose-proportional for the
pre-term and full-term newborns at concentrations of 19.3,
42.9, and 73.8 mg/liter for the 10-, 20-, and 40-mg/kg doses in
the pre-term infants. For the full-term infants, these values
were 21.7, 40.6, and 59.2 mg/liter.
Demographic modeling of pharmacokinetic parameter val-
ues. The base model without descriptors was employed to
calculate Bayesian estimates for each of the children studied.
We then explored different demographic covariates to help us
in the generation of the final population pharmacokinetic
model with demographic covariates. The general linear model
module of the SYSTAT package was used to model some
appropriate demographic variables to determine their influ-
ence on plasma clearance and V.
For meropenem plasma clearance, the demographic vari-
ables chosen as descriptors were as follows:
Clearance 0.0133 CLcr 0.1088Wt 0.261 (1)
The resulting meropenem plasma clearance estimate is in li-
ters/h. The creatinine clearance (CLcr) estimate is in units of
ml/min/1.73 m2 (estimated by the Schwartz formula [23]), and
weight (Wt) is in kg. It should be noted that weight along with
height are included in the Schwartz formula. Nevertheless, the
estimator was able to find weight as affecting clearance in
addition to the Schwartz formula-estimated creatinine clear-
ance. Overall, the regression was highly statistically significant.
The P value for CLcr was 0.00017 and for Wt was 0.036. The
regression relationship explained 67.9% of the variance (i.e.,
r2  0.679). The relationship was the same when performed
stepwise forward or stepwise backward.
For V, the physiological/demographic variable chosen was
CLcr.
Volumec 0.0.0278 CLcr 0.147 (2)
In the equation, volume is in liters and CLcr is in units of
ml/min/1.73 m2. Again, the relationship was highly statistically
significant, with a P of 
0.0001. The relationship explained
35.2% of the variance (r2  0.352). The general linear model
procedure identified a larger model (including weight) step-
wise backward but only CLcr stepwise forward. To be conser-
vative, we employed the stepwise forward procedure.
Population modeling. The population model for all infants
(n  38), performed without covariates, had a maximum-like-
lihood score of655.7. A general linear model was developed,
relating both volume of the central compartment and clear-
ance to covariates (see above). Volume was related to esti-
mated creatinine clearance. Clearance was related to weight
and estimated creatinine clearance.
Population analyses were performed with the volume and
clearance related to the covariates as indicated below:
Clearance Clearanceint AWt B CLcr (3)
Volumec Volumeint C CLcr (4)
The likelihood scores for the base model and the expanded
models are shown in Table 3. The fit of the full model to the
data was good. After the Bayesian step, the r2 was 0.977; the
TABLE 2. Demographic data and sequence of treatments of
hospitalized full-term neonates
Center/
patient no. Sex
Gestational
age (wk) Wt (kg)
Crown-heel
length (cm)
CLcra
(ml/min/
1.73 m2)
Dosing
(mg/kg)
0001/0101 M 40 3.26 52.0 51.7 40
0001/0102 F 39 3.02 47.0 60.3 20
0001/0103 M 38 3.42 53.0 39.8 10
0001/0104 M 39 3.22 53.0 39.8 20
0001/0105 M 38 3.02 47.0 41.6 40
0001/0106 M 38 2.82 49.0 40.6 10
0001/0107 F 41 3.56 51.0 56.4 20
0001/0108 M 38 3.19 49.0 41.5 10
0001/0109 F 39 3.15 49.0 48.7 40
0001/0110 F 40 4.00 52.0 48.1 10
0001/0111 M 39 2.95 48.0 49.0 40
0001/0112 M 39 4.05 50.0 34.3 20
0002/0101 M 42 2.47 49.0 55.7 40
0002/0102 F 37 2.34 43.0 20.1 20
0002/0103 M 38 3.12 50.0 31.6 10
Mean 39 3.17 49.5 43.9
SD 1 0.47 3 10.5
Min 37 2.34 43 20.1
Max 42 4.05 53 60.3
a The creatinine clearance was calculated as follows: CLcr  0.45  crown-heel
length/plasma creatinine (2).
VOL. 53, 2009 MEROPENEM PHARMACOKINETICS IN THE NEWBORN 3873
 o
n
 July 12, 2012 by Universiteitsbibliotheek
http://aac.asm
.org/
D
ow
nloaded from
 
observed meropenem concentrations were calculated as fol-
lows: 1.037  predicted meropenem concentrations  0.096.
Bias was 0.154 mg/liter; precision was 1.003 (mg/liter)2. This
is displayed in Fig. 2.
The fit of the full model prior to the Bayesian step was also
quite acceptable. The r2 was 0.742. Observed meropenem con-
centrations were calculated as follows: 0.917  predicted
meropenem concentrations  3.748. Bias was 0.259 mg/liter;
precision was 18.152 (mg/liter)2.
The final parameter values for the integrated analysis of all
38 neonates are presented in Table 4.
More information regarding the V and plasma clearance can
be obtained by examining the ranges observed for these pa-
rameters after the Bayesian step for the two populations. For
the V, the 20% to 80% bounds on volume for the pre-term and
full-term groups are 0.44 to 0.98 and 0.82 to 1.54 liters, showing
considerable overlap. However, when one examines the distri-
butions for clearance, the full-term children have a 20% to
80% range of 0.414 to 0.753 liters/h, whereas for pre-term
FIG. 1. (A) Mean (for 10 mg/kg, n 9; for 20 mg/kg, n 8; for 40 mg/kg, n 6) plasma concentrations of meropenem of hospitalized pre-term
neonates after a 30-min infusion of 10, 20, or 40 mg/kg of meropenem. (B) Mean (for 10 mg/kg, n  5; for 20 mg/kg, n  5; for 40 mg/kg, n 
4) plasma concentrations of meropenem of hospitalized full-term neonates after a 30-min infusion of 10, 20, or 40 mg/kg of meropenem.
TABLE 3. Likelihood scores of competing modelsa
Model Likelihoodscore
2 likelihood
difference df P value
Base model 655.7
Wt and CLcr (in clearance) 648.8 13.8 2 
0.001
CLcr (in vol) 648.4 0.8 1 NS
a df, degrees of freedom; NS, not significant.
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children, this range is 0.253 to 0.398 liters/h. It is clear that the
two subpopulations differ significantly in their clearances of
meropenem. Full-term infants have a substantially larger
plasma clearance for meropenem than do pre-term infants, as
could be predicted from the increased renal clearing capacity
of the full-term newborn.
Monte Carlo simulation and target attainment rates by
MIC. The log-normal distribution best regenerated the point
estimates of the mean parameter values and the estimates of
dispersion. For carbapenem antibiotics, organism maximal cell
kill occurs when the TimeMIC of free drug meets or exceeds
40% of the dosing interval (11). Thus, 40% TimeMIC of free
drug served as the target in our simulation. The target attain-
ment rates for a dose of 20 or 40 mg/kg intravenously every 8
or 12 h with constant-rate infusions of 0.5 h and 4 h are
presented in Fig. 3A (20 mg/kg) and B (40 mg/kg) for the
pre-term infants and in Fig. 3C (20 mg/kg) and D (40 mg/kg)
for the full-term infants. As can be seen in the figure, maximal
cell kill is clearly improved by the use of a prolonged (4-h)
infusion. The combination of a 40-mg/kg dose and a prolonged
infusion produces target attainments in excess of 90% out to an
MIC of 8 mg/liter for both the pre-term and full-term groups.
More recently, Tam et al. (26) have demonstrated that carbap-
enem trough concentrations need to be 1.7 times the MIC to
minimize resistant mutant amplification in Pseudomonas
aeruginosa when meropenem is administered along with an
aminoglycoside and 6.2 times the MIC to suppress resistance
when administered alone. Using these as a metric, we present
the likelihood of attaining a resistance suppression profile with
meropenem at a dose of 40 mg/kg/day every 8 h with a 4-h
infusion. This clearly demonstrates the difference between 12-
and 8-h dosing intervals and also between pre-term and full-
term populations.
DISCUSSION
Neonatal sepsis remains one of the main causes of mortality
and morbidity of newborn infants admitted to a neonatal in-
tensive care unit (1, 14, 16, 18). Furthermore, invasive infec-
tions such as pneumonia, meningitis, and necrotizing entero-
colitis threaten the newborn infant.
Meropenem is distributed in extracellular water and is ex-
creted mainly by glomerular filtration. Therefore, changes in
body water and development of renal function influence the
disposition of meropenem. Meropenem has a larger V and
lower clearance in premature neonates, and even more so
compared to adults, and dosing regimens thus have to be
adjusted accordingly. Improvement of clearance follows the
gestational age- and postnatal age-dependent increases in the
glomerular filtration rate (9). Other factors in the neonatal
intensive care unit that directly influence V or renal function,
such as extracorporeal membrane oxygenation or exposure to
indomethacin, were shown to significantly alter the neonatal
pharmacokinetics of other primarily renally excreted drugs (7,
8, 9, 27).
Meropenem pharmacokinetics have been reported in seven
pre-term neonates, showing a V of 0.74 (range, 0.24 to 1.2)
liters/kg (30). The half-life was circa 3.4 h, which is substan-
tially longer than the 1-h rate in adults (21). From the previous
study, those authors concluded that, because of the increased
half-life, a two-times-daily meropenem dose of 15 mg/kg would
suffice. Most recently, Bradley and colleagues (4) studied 37
neonates and administered single doses of 10 and 20 mg/kg
of meropenem as a 30-min infusion. These authors demon-
strated that an 8-h interval may be more appropriate for
organisms with higher MICs. They found that a 20-mg/kg,
8-h dose would provide robust coverage for their patients
but that 40 mg/kg may be necessary for some infections with
more resistant pathogens, like Pseudomonas aeruginosa. It
should be noted, however, that these data were based on
very sparse sampling, where any one patient had three blood
samples obtained on one of two schedules. In contrast, the
patients reported here had seven to nine samples obtained
for analysis.
Here we report the results of a single-dose pharmacokinetic
study of 38 newborn infants (23 pre-term and 15 full-term)
using three different doses (10, 20, and 40 mg/kg) of mero-
penem intravenously. Because of the limits on blood with-
drawal and because of ethical considerations, it was only pos-
sible to perform this study on newborns that were already
infected and required antimicrobial therapy. Because of this, it
is clear that there may have been some competition, particu-
larly at the renal tubular level between drugs being adminis-
FIG. 2. Predicted observed plot for meropenem concentrations af-
ter the Bayesian step for the total population, using the final model
(CLcr and weight in meropenem clearance—see Table 3).
TABLE 4. Final model pharmacokinetic parameter values of
meropenem in hospitalized pre-term and full-term neonatesa
Characteristic Vol(liter)
Kcp
(h1)
Kpc
(h1)
CLSLPcr
(liter/h/
ml/min/
1.73 m2)
CLSLPWt
(liter/h/kg)
CL-INT
(liter/h)
Mean 0.969 7.71 30.0 0.00112 0.0925 0.156
Median 0.883 5.862 41.6 0.00510 0.0918 0.172
Mode 0.896 0.100 44.8 0.00510 0.0460 0.0248
SD 0.527 6.67 17.9 0.00151 0.0606 0.122
a The parameter values are for the analysis of both pre- and full-term neo-
nates. Simulations for the two subpopulations employ the separate weight and
estimated creatinine clearance distributions which are shown in Tables 1 and 2.
Vol, volume of the central compartment; Kcp and Kpc, first-order intercompart-
mental transfer rate constants; CLSLPcr, the clearance slope term with estimated
creatinine clearance; CLSLPWt, the clearance slope term with weight; CL-INT,
the clearance intercept term. The estimate for meropenem clearance from the
mean values is given by the following equation: CL  0.156  0.00112  CLcr 
0.0925  Wt.
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tered at approximately the same period. We attempted to
minimize such an interaction by not administering the mero-
penem at a time when concentrations of any other competing
agent might be high. Nevertheless, it must be understood that
some interference may have taken place. However, it should
also be understood that the pharmacokinetics of meropenem
were determined in a clinically realistic setting.
The population modeling that we undertook demonstrated
clearly that meropenem V values were in the range of those
reported previously for other agents of the -lactam class.
Examination of the probability distribution of the volume for
the pre-term versus the full-term groups of newborns showed
that the means were similar and that the full-term infants,
somewhat surprisingly, were more variable in their V.
The clearances were significantly different in the two groups.
As can be seen by examining Tables 1 and 2, pre-term infants
had calculated creatinine clearances which were clearly less
than those seen in the full-term neonatal group. This is to be
expected on the basis of their gestational age (19, 27, 28, 29).
Indeed, when one compares the probability distribution of
clearance for the full population versus each of the two sub-
populations, it is clear that there is at most a 15 to 20% overlap
between the pre-term and full-term groups. We hypothesized
that this nonoverlap of meropenem plasma clearance was due,
FIG. 3. Meropenem target (40% TimeMIC  maximal kill) attainment for a 20-mg/kg dose (A) or 40-mg/kg dose (B) every 8 or 12 h in
pre-term infants. These doses are displayed for full-term infants in panels C and D.
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mainly, to the differences in estimated creatinine clearances in
the two patient populations.
These between-group differences need to be taken into ac-
count when designing dosing regimens that would have a high
likelihood of being efficacious in the empirical therapy setting.
Multiple investigators (5, 13) have demonstrated that Time
MIC is the pharmacodynamic variable most closely linked to
outcome for -lactam antibiotics. Consequently, it is important
to be able to make dosing recommendations which the clini-
cian can employ at the bedside to generate concentrations of
meropenem in the plasma which remain above the MIC of
clinically important pathogens for a relatively high percentage
of the dosing interval.
Monte Carlo simulation combined with target attainment
rate analysis has been introduced as a way of rationally eval-
uating dose and schedule as well as setting MIC breakpoints
(3), and it has been reviewed for its applicability to children
(17). This approach has been prospectively validated in a num-
ber of circumstances, both for bacteria and viruses (3, 5, 12).
We evaluated meropenem at a prospective dose and schedule
of 20 and 40 mg/kg every 8 and 12 h using the pre-term and
full-term population pharmacokinetics (Fig. 3). Maintaining
free-drug concentrations (meropenem is approximately 2%
bound) of MIC for 40% of a dosing interval achieves a
maximal cell kill (11). Examination of Fig. 3 demonstrates that
a dose of 40 mg/kg with an 8-h dosing interval produces target
attainment rates of 90% for achieving maximal cell kill at 8
mg/liter for both pre-term and full-term infants. Use of a
FIG. 3—Continued.
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prolonged (4-h) infusion markedly improves target attainment
rates for the 20-mg/kg dose. Obviously, antimicrobial chemo-
therapy is a balance between efficacy and toxicity. Meropenem
has little in the way of concentration-dependent toxicity, but
the balance should be explicitly judged when the decision for a
20-mg/kg versus a 40-mg/kg dose is to be made.
As indicated above, previous work in a smaller number of
neonates (30) resulted in a recommendation for a 12-h dosing
interval. It is likely that such a recommendation would be
successful for infections where non-pseudomonal or non-Acin-
etobacter isolates were being treated, where MICs would be
highly likely to be 2 mg/liter. The circumstance of the infec-
tion becomes clear after pathogen identification. It may be
prudent, then, to choose an 8-h interval until the pathogen is
identified and an MIC is obtained.
These data indicate that 20 to 40 mg/kg with an 8-h dosing
interval should provide robust coverage for the vast majority of
nosocomially acquired pathogens seen in this population. If the
20-mg/kg dose is chosen, consideration should be given to the
prolonged (4-h) infusion. Care needs to be exercised for clini-
cians in settings where there is a high likelihood of methicillin-
resistant Staphylococcus aureus, as meropenem would not be
adequate empirical therapy for this pathogen. In addition,
meropenem has been given to children at doses of 40 mg/kg
every 8 h and has been well tolerated (empirical treatment of
meningitis). The clinician’s choice of dose, schedule, and in-
terval should be weighted upon the probability of target attain-
ment versus the probability of toxicity, modulated by the MIC
distribution of likely pathogens present in their specific insti-
tution.
Finally, given the rate of loss of antibiotics from the physi-
cian’s armamentarium due to resistance, regimens that help
suppress this resistance should be considered, if the toxicity
price is not great. Figure 4 shows the target attainment for
achieving a trough value of free drug 1.7 times a baseline MIC
(combination therapy with an aminoglycoside) and 6.2 times a
baseline MIC (monotherapy with meropenem), a target pro-
posed by Tam et al. (26) for resistance suppression for Pseudo-
monas aeruginosa. For an 8-h interval and a 4-h infusion with
a 40-mg/kg dose, this target is met 80% of the time for both
pre-term and full-term neonates out to an MIC of 2 mg/liter
when combined with an aminoglycoside, which encompasses
the vast majority of the wild-type population sensitivity of
Pseudomonas aeruginosa to meropenem. For monotherapy, the
resistance suppression goal falls below 79% after an MIC of 1.0
mg/liter. This provides another reason to favor the large dose
every 8 h with a 4-h infusion, at least empirically.
These findings need to be prospectively validated in the
clinic. Furthermore, we would like to stress that the aforemen-
tioned recommendations are primarily derived from pre-term
infants with gestational ages of more than 30 weeks, because
only one infant was studied with a gestational age of less than
30 weeks.
Data on the pharmacokinetics of meropenem in pre-term
infants with gestational ages of less than 30 weeks are still
needed before doses and schedules of meropenem can be
calculated at the bedside for this very young population.
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